The role of ADAM17 in metabolic inflammation

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 12-17

  Menghini, Rossella ^a   Fiorentino, Loredana ^a   Casagrande, Viviana ^a   Lauro, Renato ^a   Federici, Massimo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Inflammation; Insulin resistance; Macrophages; Metalloproteinase; Obesity; Steatosis

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; DIABETES MELLITUS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; STEATOSIS;

ADAM PROTEINS; ATHEROSCLEROSIS; HUMANS; INSULIN RESISTANCE; OBESITY; VASCULITIS;

EID: 84876787262     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.024     Document Type: Review

References (70)

1. Scheller J., Chalaris A., Garbers C., et al. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends in Immunology 2011, 32:380-387.
2. Peschon J.J., Slack J.L., Reddy P., et al. An essential role for ectodomain shedding in mammalian development. Science (New York, N.Y) 1998, 282:1281-1284.
3. Solomon K.A., Pesti N., Wu G., et al. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. Journal of Immunology 1999, 163:4105-4108.
4. Lorenzen I., Lokau J., Dusterhoft S., et al. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Letters 2012, 586:1093-1100.
5. Nuttall R.K., Sampieri C.L., Pennington C.J., et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Letters 2004, 563:129-134.
6. Xu P., Liu J., Sakaki-Yumoto M., et al. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Science Signaling 2012, 5:ra34.
7. McIlwain D.R., Lang P.A., Maretzky T., et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science (New York, N.Y) 2012, 335:229-232.
8. Adrain C., Zettl M., Christova Y., et al. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science (New York, N.Y) 2012, 335:225-228.
9. Gill S.E., Huizar I., Bench E.M., et al. Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. The American Journal of Pathology 2010, 176:64-73.
10. Federici M., Hribal M.L., Menghini R., et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. The Journal of Clinical Investigation 2005, 115:3494-3505.
11. Chavey C., Mari B., Monthouel M.N., et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. The Journal of Biological Chemistry 2003, 278:11888-11896.
12. Cardellini M., Menghini R., Luzi A., et al. Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness. Diabetes 2011, 60:3265-3270.
13. Andersson C.X., Gustafson B., Hammarstedt A., et al. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes/metabolism Research and Reviews 2008, 24:595-603.
14. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (New York, N.Y) 1993, 259:87-91.
15. Jellema A., Plat J., Mensink R.P. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. European Journal of Clinical Investigation 2004, 34:766-773.
16. Neels J.G., Olefsky J.M. Inflamed fat: what starts the fire?. The Journal of Clinical Investigation 2006, 116:33-35.
17. Bouhlel M.A., Derudas B., Rigamonti E., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metabolism 2007, 6:137-143.
18. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. The Journal of Clinical Investigation 2007, 117:175-184.
19. Kaneko H., Anzai T., Horiuchi K., et al. Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis 2011, 218:470-478.
20. Menghini R., Casagrande V., Menini S., et al. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 2012, 61:454-462.
21. Casagrande V., Menghini R., Menini S., et al. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2012, 32:74-81.
22. Wang Y., Sul H.S. Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Molecular and Cellular Biology 2006, 26:5421-5435.
23. Gelling R.W., Yan W., Al-Noori S., et al. Deficiency of TNFalpha converting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype in mice. Endocrinology 2008, 149:6053-6064.
24. Serino M., Menghini R., Fiorentino L., et al. Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007, 56:2541-2546.
25. Kaneko H., Anzai T., Horiuchi K., et al. Tumor necrosis factor-alpha converting enzyme inactivation ameliorates high-fat diet-induced insulin resistance and altered energy homeostasis. Circulation Journal 2011, 75:2482-2490.
26. Menghini R., Menini S., Amoruso R., et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 2009, 136:663-672 e664.
27. Rask-Madsen C., Dominguez H., Ihlemann N., et al. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 2003, 108:1815-1821.
28. Ciaraldi T.P., Carter L., Mudaliar S., et al. Effects of tumor necrosis factor-alpha on glucose metabolism in cultured human muscle cells from nondiabetic and type 2 diabetic subjects. Endocrinology 1998, 139:4793-4800.
29. Uysal K.T., Wiesbrock S.M., Marino M.W., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
30. Hotamisligil G.S., Budavari A., Murray D., et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. The Journal of Clinical Investigation 1994, 94:1543-1549.
31. Rui L., Aguirre V., Kim J.K., et al. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. The Journal of Clinical Investigation 2001, 107:181-189.
32. Plomgaard P., Bouzakri K., Krogh-Madsen R., et al. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005, 54:2939-2945.
33. Steinberg G.R., Michell B.J., van Denderen B.J., et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metabolism 2006, 4:465-474.
34. de Alvaro C., Teruel T., Hernandez R., et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. The Journal of Biological Chemistry 2004, 279:17070-17078.
35. Austin R.L., Rune A., Bouzakri K., et al. siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 2008, 57:2066-2073.
36. Monroy A., Kamath S., Chavez A.O., et al. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 2009, 52:2169-2181.
37. Cardellini M., Menghini R., Martelli E., et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009, 58:2396-2401.
38. Su Z., Tsaih S.W., Szatkiewicz J., et al. Candidate genes for plasma triglyceride, FFA, and glucose revealed from an intercross between inbred mouse strains NZB/B1NJ and NZW/LacJ. Journal of Lipid Research 2008, 49:1500-1510.
39. Swindell W.R. Genes and gene expression modules associated with caloric restriction and aging in the laboratory mouse. BMC Genomics 2009, 10:585.
40. Fiorentino L., Vivanti A., Cavalera M., et al. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology (Baltimore, Md) 2010, 51:103-110.
41. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. The Journal of Clinical Investigation 2008, 118:829-838.
42. Feldstein A.E., Werneburg N.W., Canbay A., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (Baltimore, Md) 2004, 40:185-194.
43. Mato J.M., Martinez-Chantar M.L., Lu S.C. Methionine metabolism and liver disease. Annual Review of Nutrition 2008, 28:273-293.
44. de Meijer V.E., Le H.D., Meisel J.A., et al. Tumor necrosis factor alpha-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PloS One 2011, 6:e25587.
45. Fukumura D., Ushiyama A., Duda D.G., et al. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circulation Research 2003, 93:e88-97.
46. Qi J.H., Ebrahem Q., Moore N., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine 2003, 9:407-415.
47. Murthy A., Defamie V., Smookler D.S., et al. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. The Journal of Clinical Investigation 2010, 120:2731-2744.
48. Swendeman S., Mendelson K., Weskamp G., et al. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circulation Research 2008, 103:916-918.
49. Horiuchi K., Kimura T., Miyamoto T., et al. Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. Journal of Immunology 2007, 179:2686-2689.
50. Weskamp G., Mendelson K., Swendeman S., et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circulation Research 2010, 106:932-940.
51. Ashley E.A., Ferrara R., King J.Y., et al. Network analysis of human in-stent restenosis. Circulation 2006, 114:2644-2654.
52. Canault M., Peiretti F., Kopp F., et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006, 187:82-91.
53. Canault M., Leroyer A.S., Peiretti F., et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. The American Journal of Pathology 2007, 171:1713-1723.
54. Donners M.M., Wolfs I.M., Olieslagers S., et al. A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:2188-2195.
55. Oksala N., Levula M., Airla N., et al. ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries-Tampere vascular study. Annals of Medicine 2009, 41:279-290.
56. Johnson J.L., Sala-Newby G.B., Ismail Y., et al. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:1647-1653.
57. Dreymueller D., Pruessmeyer J., Groth E., et al. The role of ADAM-mediated shedding in vascular biology. European Journal of Cell Biology 2012, 91:472-485.
58. Furfaro A.L., Sanguineti R., Storace D., et al. Metalloproteinases and advanced glycation end products: coupled navigation in atherosclerotic plaque pathophysiology?. Experimental and Clinical Endocrinology and Diabetes 2012, 120:586-590.
59. George S.J., Wan S., Hu J., et al. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 2011, 124:S135-S142.
60. Reiss K., Cornelsen I., Husmann M., et al. Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity. The Journal of Biological Chemistry 2011, 286:26931-26942.
61. Blankenberg S., Rupprecht H.J., Bickel C., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.
62. Pradhan A.D., Rifai N., Ridker P.M. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002, 106:820-825.
63. Ray K.K., Morrow D.A., Shui A., et al. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). The American Journal of Cardiology 2006, 98:861-865.
64. Horiuchi T., Mitoma H., Harashima S., et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010, 49:1215-1228.
65. Richards F.M., Tape C.J., Jodrell D.I., et al. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PloS One 2012, 7:e40597.
66. Milne J.C., Lambert P.D., Schenk S., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
67. Murphy G., Murthy A., Khokha R. Clipping, shedding and RIPping keep immunity on cue. Trends in Immunology 2008, 29:75-82.
68. Menge T., Zhao Y., Zhao J., et al. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Science Translational Medicine 2012, 4:161ra150.
69. Fiorentino L. Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. Embo Molecular Medicine, in press.
70. Monteleone I., Federici M., Sarra M., et al. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. Gastroenterology 2012, 143:1277-1287. e1271-1274.